Company news

Cosmos Health Inc. (NASDAQ:COSM) news

Cosmos Health Inc. news releases on 6ix. Latest, Oct 7, 2026: Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year…

Cosmos Health Inc. (NASDAQ:COSM) news

Press releases & updates

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure, Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution from Conversions

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases

Cosmos Health Launches Subscription Model

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases

Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases

Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases

Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases

Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace

Cosmos Health Authorizes Up to $5 Million Share Repurchase Program

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin

Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency

Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants